Open AccessClinical Experience on Use of Oral EGFR-TKIs as First-line Treatment of Advanced NSCLC from a Tertiary Care Centre in North India and Implications of Skin Rash
Author(s) -
Navneet Singh,
G Kumbar Vishwanath,
Ashutosh N. Aggarwal,
Digambar Behera
Publication year - 2022
Publication title -
indian journal of chest diseases and allied sciences
Language(s) - English
Resource type - Journals
ISSN - 0377-9343
DOI - 10.5005/ijcdas-56-3-149
Subject(s) - medicine , rash , gefitinib , lung cancer , erlotinib , odds ratio , adverse effect , retrospective cohort study , cancer , epidermal growth factor receptor